MRI Outcomes in a Placebo-Controlled Trial of Natalizumab in Relapsing MS
Neurol 68:1390-1401, Miller,D.H.,et al, 2007

Natural History of Multiple Sclerosis with Childhood Onset
NEJM 356:2603-2613, Renoux,C.,et al, 2007

Natalizumab for Multiple Sclerosis
NEJM 356:2622-2629, Ransohoff,R.M., 2007

Neuropsychiatric Syndromes Associated With Multiple Sclerosis
J Neurol 254:II/73-II/76, Feinstein,A., 2007

Natalizumab (Tysabri) Treatment for Relapsing Multiple Sclerosis
The Neurologist 13:182-187, Johnson,K.P., 2007

Effect of Early Verus Delayed Interferon Beta-1b Treatment on Disability After a First Clinical Event Suggestive of Multiple Sclerosis: A 3-Year Follow-Up Analysis of the BENEFIT Study
Lancet 370:389-397, Kappos,L.,et al, 2007

What Do We Really See When We Look at Magnetic Resonance Images?
Ann Neurol 62:207-208, Filippi,M. &Hartung,H.-P., 2007

Parental Transmission of MS in a Population-Based Canadian Cohort
Neurol 69:1208-1212,1202, Herrera,B.M.,et al, 2007

Thalamic Atrophy and Cognition in Multiple Sclerosis
Neurol 69:1213-1223, Houtchens,M.K.,et al, 2007

Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007

Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007

The Incidence and Significance of Anti-Natalizumab Antibodies: Results from AFFIRM and SENTINEL
Neurol 69:1391-1403,1396, Calabresi,P.A.,et al, 2007

Guidelines For Using Proton MR Spectroscopy in Multicenter Clinical MS Studies
Neurol 69:1942-1952, De Stefano,N.,et al, 2007

Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007

Quantitative Assessment of Iron Accumulation in the Deep Gray Matter of Multiple Sclerosis by Magnetic Field Correlation Imaging
AJNR 28:1639-1644, Ge,Y.,et al, 2007

Acute Fulminant Demyelinating Disease: A Descriptive Study of 60 Patients
Arch Neurol 64:1426-1432, de Seze,J.,et al, 2007

Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 69:1552-1553, Sorenson,P.S. &Bertolotto,A., 2007

How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007

Differential Diagnosis of Bilateral Thalamic Lesions
Clin Neuroradiol 17:3-22, Linn,J.,et al, 2007

The Differential Diagnosis of Multiple Sclerosis
Neurologist 13:57-72, Rolak, L.A.,et al, 2007

Diffusion-Weighted MR Imaging Characteristics of an Acute Strokelike Form of Multiple Sclerosis
AJNR 27:1006-1008, Rosso,C.,et al, 2006

Multiple Sclerosis in Twins From Continental Italy and Sardinia: A Nationwide Study
Ann Neurol 59:27-34, Ristori,G.,et al, 2006

Standardized MR Imaging Protocol for Multiple Sclerosis:Consortium of MS Centers Consensus Guidelines
AJNR 27:455-461, Simon,J.H.,et al, 2006

Safety and Tolerability of Interferon Beta-1b in Pediatric Multiple Sclerosis
Neurol 66:472-476, Banwell,B.,et al, 2006

Clinically Isolated Syndromes, A New Oligoclonal Band Test Accurately Predicts Conversion to MS
Neurol 66:576-578, Masjuan,J.,et al, 2006

What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006

Multiple Sclerosis - The Plaque and Its Pathogenesis
NEJM 354:942-955, Frohman,E.M.,et al, 2006

Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006

IM Interferon B-1a Delays Definite Multiple Sclerosis 5 Years After a First Demyelinating Event
Neurol 66:678-684, CHAMPIONS Study Group, 2006

Gray and White Matter Brain Atrophy and Neuropsychological Impairment in Multiple Sclerosis
Neurol 66:685-692, Sanfilipo,M.P.,et al, 2006

Diagnosis and Treatment of Multiple Sclerosis
BMJ 332:525-527, Murray,T.J., 2006

Magnetic Resonance Imaging as a Surrogate Outcome Measure of Disability in Multiple Sclerosis: Have We Been Overly Harsh in Our Assessment?
Ann Neurol 59:597-605, Goodin,D.S., 2006

Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should be Treated at the Time of Diagnosis
Arch Neurol 63:614-619, Frohman,E.M.,et al, 2006

Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis
Arch Neurol 63:611-619, Pittock,S.J.,et al, 2006

Increase in Multiple Sclerosis Relapse Rate Following in vitro Fertilization
Neurol 66:1280-1281, Laplaud,D.-A.,et al, 2006

Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006

MRI T2 Lesion Burden in Multiple Sclerosis. A Plateauing Relationship with Clinical Disability.
Neurol 66:1384-1389, Li,D.K.B.,et al, 2006

Multiple Sclerosis: New Insights and Trends
AJNR 27:954-957, Inglese,M., 2006

Accuracy of Magnetic Resonance Imaging for the Diagnosis of Multiple Sclerosis: Systematic Review
BMJ 332:875-878, Whiting P.,et al, 2006

Multiple Sclerosis: The Role of MR Imaging
AJNR 27:1165-1176, Ge,Y., 2006

Tetanus Vaccination and Risk of Multiple Sclerosis: A Systematic Review
Neurol 67:212-215, Hernn,M.A.,et al, 2006

The Clinical Features, MRI Findings, and Outcome of Optic Neuritis in Children
Neurol 67:258-262, Wilejto,M.,et al, 2006

Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006

Premenstrual Multiple Sclerosis Pseudoexacerbations: Role of Body Temperature and Prevention With Aspirin
Arch Neurol 63:1005-1008, Wingerchuk,D.M. &Rodriguez,M., 2006

Significance of T2 Lesions in Multiple Sclerosis: A 13-Year Longitudinal Study
Ann Neurol 60:236-242, Rudick,R.A.,et al, 2006

Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006

Does High-Field MR Imaging Have an Influence on the Classification of Patients with Clinically Isolated Syndromes According to Current Diagnostic MR Imaging Criteria for Multiple Sclerosis
AJNR 27:1794-1798, Wattjes,M.P.,et al, 2006

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006

Baseline MRI Predicts Future Attacks and Disability in Clinically Isolated Syndromes
Neurol 67:968-972, Tintore,M.,et al, 2006